Clinical Trial

A Study of LM-350 in Subjects With Advanced Solid Tumours

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-350 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explore the relationship between the biomarkers and the anti-tumor activity of LM-350. For Phase II Dose Expansion Stage, to assess the preliminary anti-tumor activity of LM-350 in patients with advanced solid tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-01; most recent amendment 2026-01-22.
Status change: Not Yet Recruiting → Recruiting 2026-01-22
Trial Details
NCT Number NCT07112222
Lead Sponsor LaNova Medicines Limited
Conditions Malignant Tumors
Enrollment 80 participants
Start Date 2025-08-28
Primary Completion 2028-06-30 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-26